The short version of Certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-03. Anything still debated is marked as such rather than presented as settled.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
== Business, finance, and economics == Safety improvement plan, a plan for improving safety Sales incentive plan, a type of employee incentive program Securities information processor, the part of public infrastructure for disseminating market data in the United States Share Incentive Plan, a UK government approved employee plan Systematic investment plan, an investment strategy
=== Glycoprotein Ia / IIa complex (GPIa / IIa = integrin α2β1) === This is a receptor for collagen type I and IV. It consists of two subunits (α2 and β1). The α2 subunit includes a domain homologous to von Willebrand factor domain binding to collagen. The β1 subunit has four cysteine-rich regions and a structure similar to other β-integrins. The interaction with collagen leads to stabilization of the platelets. The surface expression of this complex shows high variability, particularly in relation to the polymorphism of GPIa subunit gene. Different opinions exist on the importance of C - T point mutation at position 807, which is believed to be associated with the risk of myocardial infarction or ischemic stroke.
== Interactions == Contraindications include prior treatment (within the past 2 weeks) with MAOIs such as phenelzine and tranylcypromine, due to the potential for serotonin syndrome. Its use should also be avoided in those with known hypersensitivities to fluoxetine or any of the other ingredients in the formulation used. Its use in those concurrently receiving pimozide or thioridazine is also advised against. In case of short-term administration of codeine for pain management, it is advised to monitor and adjust dosage. Codeine might not provide sufficient analgesia when fluoxetine is co-administered. If opioid treatment is required, oxycodone use should be monitored since oxycodone is metabolized by the cytochrome P450 (CYP) enzyme system and fluoxetine and paroxetine are potent inhibitors of CYP2D6 enzymes. This means combinations of codeine or oxycodone with fluoxetine antidepressant may lead to reduced analgesia. In some cases, use of dextromethorphan-containing cold and cough medications with fluoxetine is advised against, due to fluoxetine increasing serotonin levels, as well as the fact that fluoxetine is a cytochrome P450 2D6 inhibitor, which causes dextromethorphan to not be metabolized at a normal rate, thus increasing the risk of serotonin syndrome and other potential side effects of dextromethorphan. Patients who are taking NSAIDs, antiplatelet drugs, anticoagulants, omega-3 fatty acids, vitamin E, and garlic supplements must be careful when taking fluoxetine or other SSRIs, as they can sometimes increase the blood-thinning effects of these medications.
Sources: en.wikipedia.org
== List of specialties recognized in the European Union and European Economic Area == The European Union publishes a list of specialties recognized in the European Union, and by extension, the European Economic Area. There is substantial overlap between some of the specialties and it is likely that for example "Clinical radiology" and "Radiology" refer to a large degree to the same pattern of practice across Europe.
=== Receptor binding === As shown in Table 1, adenylyl cyclase and cAMP assays were used in various functional studies to determine the amount of cAMP inhibition by two CRH1 receptor antagonists: antalarmin and CP-154,526.
== Awards and honors == Sheiner received the Oscar B. Hunter Award, the highest honor of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in 2004. He was given an Honorary Doctorate from Uppsala University, Sweden in 1995 and received the Rawls Palmer Progress in Medicine Award of the ASCPT in 1989. Posthumously, several awards have been named in Sheiner's honor, including the International Society of Pharmacometrics (ISoP) Lewis B. Sheiner Lecturer Award and the ASCPT's Sheiner-Beal Pharmacometrics Award.
== History == In 1976, two cats were described with diabetes mellitus and acidophilic pituitary adenomas. Whilst growth hormone levels were not measured it was proposed that growth hormone excess from the tumours was the cause of the diabetes. In the following three decades further cases would only be written about infrequently and feline hypersomatotropism was considered a rare disease. This was challenged in 2007 after a study looking at the IGF-1 levels in cats with diabetes found a marked increase in 32% of cats. Growth hormone excess induced by progestogens in dogs was first described in the 1970s and 1980s. In 1980 a crossbred Belgian Shepherd bitch with acromegaly that had been administered excessive amounts of medroxyprogesterone acetate (MPA); following cessation of MPA administration symptoms improved and hormone levels returned to normal. In 1981 it was reported that fifteen bitches receiving MPA injections to prevent oestrus. All fifteen showed signs of acromegaly and thirteen showed hyperglycaemia. Clinical signs were improved after cessation of MPA. Later studies would confirm an association between progestogen administration and acromegaly, glucose intolerance, and diabetes mellitus.
Sources: en.wikipedia.org
Rusfertide, sold under the brand name Mimrylo, is a medication used for the treatment of polycythemia vera. It is a hepcidin mimetic. It was developed by Protagonist Therapeutics in partnership with Takeda Pharmaceuticals. It is given by subcutaneous injection. The most common adverse reactions include injection site reactions and anemia. Rusfertide was approved for medical use in the United States in August 2026. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body.
DBNPA (2,2-dibromo-3-nitrilopropionamide) is a brominated acetamide. Its synonyms include 2,2-dibromo-2-carbamoylacetonitrile, α,α-dibromo-α-cyanoacetamide, and dibromocyanoacetamide. The physical appearance of DBNPA is an off-white solid at ambient temperatures with a mild antiseptic odor and is often sold in powder form. DBNPA is often used as an algicide, bactericide and fungicide in industrial water treatment systems and as a preservative used in the manufacture of paper, glues, coatings, enhanced oil recovery systems and metalworking.
== Etymology == The Oxford English Dictionary suggests that the European languages generally appear to have adopted the name from Turkish kahveh, about 1600, perhaps through Italian caffè. Arab qahwah, in Turkish pronounced kahveh, the name of the infusion or beverage; said by Arab lexicographers to have originally meant "wine" or some type of wine, and to be a derivative of a verb-root qahiya "to have no appetite". Another common theory is that the name derives from Kaffa Province, Ethiopia, where the species may have originated.
Later during the war, Kitchener attempted to form a Boer Police Force, as part of his efforts to pacify the occupied areas and effect a reconciliation with the Boer community. The members of this force were despised as traitors by the Boers still in the field. Boers who attempted to remain neutral after giving their parole to British forces were derided as "hensoppers" (hands-uppers) and often coerced into giving support to the Boer guerrillas (which was one reason for British scorched earth campaigns throughout the countryside and detention of Boers in concentration camps, to deny anything of use to the guerrillas). Like the Canadian, and particularly the Australian and New Zealand contingents, many volunteer units formed by South Africans were "light horse" or mounted infantry, well-suited to the countryside and manner of warfare. Some regular British officers scorned their comparative lack of formal discipline, but the light horse units were hardier and more suited to campaigning than the overloaded British cavalry, who were still obsessed with the charge by lance or sabre. At their peak, 24,000 South Africans served in the field in "colonial" units. Notable units (in addition to the Imperial Light Horse) were the South African Light Horse, Rimington's Guides, Kitchener's Horse and the Imperial Light Infantry.
The 5-HT3 receptors are a subclass of serotonin (5-HT) receptors. They belong to the Cys-loop superfamily of ligand-gated ion channels (LGICs) and differ structurally and functionally from all other serotonin receptors, which are G protein-coupled receptors. 5-HT3 receptors are cation channels, that is, they are permeable to sodium (Na), potassium (K), and calcium (Ca) ions and mediate neuronal depolarization and excitation within the central and peripheral nervous systems. As with other ligand gated ion channels, the 5-HT3 receptor consists of five subunits arranged around a central ion conducting pore. Binding of the neurotransmitter serotonin (or 5-hydroxytryptamine) to the 5-HT3 receptor opens the channel, which, in turn, leads to an excitatory response in neurons. The rapidly activating, desensitizing, inward current is predominantly carried by sodium and potassium ions. 5-HT3 receptors have a negligible permeability to anions. They are most closely related by homology to the nicotinic acetylcholine receptor.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.